Skip to content
Dx

ICD-10-CM 2027 diagnosis code

G37.81Myelin oligodendrocyte glycoprotein antibody disease

✓ Billable / specificCC — complication/comorbidity

G37.81 is a valid, billable ICD-10-CM code for myelin oligodendrocyte glycoprotein antibody disease. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Looking up by condition? See ICD-10 code for MOGAD.

Code last changed in FY2024 (effective October 1, 2023). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About G37.81

G37.81 is the ICD-10-CM diagnosis code for Myelin oligodendrocyte glycoprotein antibody disease. It belongs to category G37 (other demyelinating diseases of central nervous system), block G35-G37 (demyelinating diseases of the central nervous system) and chapter 6 (diseases of the nervous system). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within G37.8 (other specified demyelinating diseases of central nervous system), G37.81 is specifically for Myelin oligodendrocyte glycoprotein antibody disease. Related codes cover other specified demyelinating diseases of central nervous system (G37.89).

As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.

In MS-DRG v44.0, it is part of the grouping logic for DRG 058 (Multiple Sclerosis and Cerebellar Ataxia with MCC, relative weight 1.8438), DRG 059 (Multiple Sclerosis and Cerebellar Ataxia with CC, relative weight 1.2002) and DRG 060 (Multiple Sclerosis and Cerebellar Ataxia without CC/MCC, relative weight 0.9247), in MDC 01 (Diseases and Disorders of the Nervous System), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It was added in FY2024, effective October 1, 2023.

Coding notes

Applicable toConditions and synonyms classified to this code
  • MOG antibody disease
Code alsoTwo codes may be needed; sequencing depends on circumstances
  • associated manifestations, if known, such as:
  • noninfectious acute disseminated encephalomyelitis (G04.81)
  • neuromyelitis optica (G36.0)

Notes that apply from higher levels

Instructions written at a parent level also apply to G37.81.

Broader instructions also apply from Chapter 6: Diseases of the nervous system.

Alphabetic index entries

3 entries

Terms in the official ICD-10-CM index that lead to G37.81.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2024 (effective 10/1/2023): Added
  • No changes since FY2024.

Common questions about G37.81

Is G37.81 billable?

Yes. G37.81 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can G37.81 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict G37.81 as a principal diagnosis.

Is G37.81 a CC or MCC?

G37.81 is a CC (complication or comorbidity) under MS-DRG v44.0, unless excluded by the principal diagnosis.

What DRG does G37.81 group to?

G37.81 is used in the MS-DRG v44.0 logic for MS-DRG 058 (Multiple Sclerosis and Cerebellar Ataxia with MCC), MS-DRG 059 (Multiple Sclerosis and Cerebellar Ataxia with CC) and MS-DRG 060 (Multiple Sclerosis and Cerebellar Ataxia without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.